Opinion of the Transparency Council – active substances fenoteroli hydrobromidum + ipratropii bromidum

At its meeting on 18 July 2022 the Transparency Council adopted Opinion No. 116/2022 on active substance fenoteroli hydrobromidum + ipratropii bromidum for the following off-label indications: cystic fibrosis; bronchopulmonary dysplasia; ciliary dyskinesia.

Publication in Public Information Bulletin (BIP)